Restless Legs Syndrome Market Size

Restless Legs Syndrome Market Analysis

The Restless Legs Syndrome Market size is estimated at USD 691.55 million in 2024, and is expected to reach USD 891.44 million by 2029, growing at a CAGR of 5.21% during the forecast period (2024-2029).

During the pandemic period, the market witnessed a significant impact attributed to the increased burden of restless legs syndrome (RLS) in COVID-19-infected patients. For instance, as per the article published by the Journal of Clinical Sleep Medicine in May 2022, a study was conducted in the United States that showed that sleep disturbance was common in long-COVID-19 (LC) patients and RLS was often reported after the viral infection. This led to the increased demand for RLS treatment medications, which has further impacted the market growth during the pandemic period. However, the market is gradually stabilizing as COVID-19 cases declined to result in a return to the pre-pandemic level. Therefore, the COVID-19 pandemic accelerated the treatment of RLS and created lucrative opportunities for market growth in the studied period.

The rise in the prevalence of restless leg syndrome, the high unmet need for treatment, and the increasing geriatric population are key factors responsible for the market's growth. For instance, according to a study published by Frontiers Media S.A. in March 2022, the reported prevalence of restless legs syndrome varied between 3.9% and 14.3% globally. According to the same study, the prevalence of restless legs syndrome was higher among females than males. Thus, the high prevalence of RLS is expected to enhance market growth.

Furthermore, according to a study published in eClinicalMedicine in April 2022, about 25% of people with diabetes showed signs of restless legs syndrome, and people with diabetes had an increased risk of developing restless legs syndrome compared to people without diabetes. Also, according to the data published by the CDC, in June 2022, 37.3 million people in the United States had diabetes, which is approximately 11.3% of the United States population. Thus, the high prevalence of diabetes associated with restless leg syndrome is expected to drive market growth over the forecast period.

Additionally, various initiatives taken by the key market players, such as product launches, mergers, acquisitions, and partnerships, are expected to boost the market's growth during the forecast period. For instance, in April 2022, an East Carolina University researcher landed a licensing agreement with Clemens, a professor in the Brody School of Medicine's Department of Physiology, for a patent to treat restless legs syndrome and helped them secure the patent and an eventual licensing agreement with Emalex Biosciences. The partnership gave Emalex potential use for its D1 receptor antagonist, ecopipam. Such an initiative is expected to drive the growth of the market.

Thus, owing to the factors above, such as the high prevalence of restless legs syndrome and the rising initiatives by market players, the market studied is anticipated to grow over the analysis period. However, the side effects associated with restless syndrome treatments are expected to restrain the market's growth.